Table 2 Characteristics of breast primary in study population
Number of patients (%) | |
|---|---|
Stage at diagnosis | |
1 | 20 (17.2) |
2 | 52 (44.8) |
3 | 30 (25.9) |
4 | 14 (12.2) |
Grade | |
1 | 8 (6.9) |
2 | 51 (44) |
3 | 57 (49.1) |
Nodal status | |
Negative | 23 (19.8) |
Positive | 93 (80.2) |
HR status | |
ER and/or PR positive | 74 (63.8) |
ER and PR negative | 42 (36.2) |
HER2 status | |
Negative | 79 (68.1%) |
Positive | 37 (31.8%) |
Neoadjuvant or Adjuvant treatment | |
Nil or non-compliant | 14 (13.7) |
Endocrine only | 6 (5.9) |
Non-anthracycline chemotherapy | 11 (10.8) |
Anthracycline-base chemotherapy | 38 (37.3) |
Anthracycline and taxane | 29 (28.4) |
Taxane only | 4 (3.9) |
Adjuvant trastuzumab | 10 (8.6) |
Disease-free interval, median (range) | 36.3 (26.2 – 135) |